PL4337652T3 - Inhibitory NLRP3 - Google Patents

Inhibitory NLRP3

Info

Publication number
PL4337652T3
PL4337652T3 PL22728228.2T PL22728228T PL4337652T3 PL 4337652 T3 PL4337652 T3 PL 4337652T3 PL 22728228 T PL22728228 T PL 22728228T PL 4337652 T3 PL4337652 T3 PL 4337652T3
Authority
PL
Poland
Prior art keywords
nlrp3 inhibitors
nlrp3
inhibitors
Prior art date
Application number
PL22728228.2T
Other languages
English (en)
Inventor
Lea Aurelie BOUCHE
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina MESCH
Andreas Michael TOSSTORFF
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL4337652T3 publication Critical patent/PL4337652T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
PL22728228.2T 2021-05-12 2022-05-10 Inhibitory NLRP3 PL4337652T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (1)

Publication Number Publication Date
PL4337652T3 true PL4337652T3 (pl) 2025-07-14

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22728228.2T PL4337652T3 (pl) 2021-05-12 2022-05-10 Inhibitory NLRP3

Country Status (26)

Country Link
US (1) US20240208928A1 (pl)
EP (2) EP4609865A3 (pl)
JP (1) JP7869248B2 (pl)
KR (1) KR20240007152A (pl)
AR (1) AR125818A1 (pl)
AU (1) AU2022275300A1 (pl)
BR (1) BR112023023527A2 (pl)
CA (1) CA3214626A1 (pl)
CL (1) CL2023003312A1 (pl)
CO (1) CO2023016204A2 (pl)
CR (1) CR20230529A (pl)
DK (1) DK4337652T3 (pl)
ES (1) ES3031704T3 (pl)
FI (1) FI4337652T3 (pl)
HR (1) HRP20250632T1 (pl)
HU (1) HUE071498T2 (pl)
IL (1) IL307188A (pl)
LT (1) LT4337652T (pl)
MA (1) MA64323B1 (pl)
MX (1) MX2023012907A (pl)
PE (1) PE20240126A1 (pl)
PL (1) PL4337652T3 (pl)
RS (1) RS66893B1 (pl)
SI (1) SI4337652T1 (pl)
TW (1) TWI915553B (pl)
WO (1) WO2022238347A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
MX2024008548A (es) * 2022-01-07 2024-07-19 Transthera Sciences Nanjing Inc Inhibidor del inflamosoma nlrp3 y uso del mismo.
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US20260167637A1 (en) * 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
JP2025540202A (ja) * 2022-12-07 2025-12-11 エフ. ホフマン-ラ ロシュ アーゲー Nlrp3阻害のモジュレーターとしての新規化合物
US20260234123A1 (en) * 2023-01-27 2026-08-13 Mwyngil Therapeutics, Inc. Inhibitors of NLRP3
EP4683918A1 (en) * 2023-03-20 2026-01-28 Insilico Medicine IP Limited Nlrp3 inflammasome inhibitors and uses thereof
JP2026509587A (ja) 2023-03-23 2026-03-19 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 トリアジン化合物およびその使用
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
KR20260029291A (ko) 2023-06-29 2026-03-04 에프. 호프만-라 로슈 아게 Nlrp3 억제제로서의 트리아진 유도체
CN121586712A (zh) 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
EP4777504A1 (en) * 2023-09-12 2026-07-22 Zomagen Biosciences Ltd Nlrp3 modulators
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物

Also Published As

Publication number Publication date
EP4337652B1 (en) 2025-04-09
BR112023023527A2 (pt) 2024-01-30
DK4337652T3 (da) 2025-06-10
PE20240126A1 (es) 2024-01-22
FI4337652T3 (fi) 2025-06-20
CO2023016204A2 (es) 2023-12-11
WO2022238347A1 (en) 2022-11-17
SI4337652T1 (sl) 2025-07-31
EP4337652A1 (en) 2024-03-20
EP4609865A3 (en) 2025-10-29
JP2024517917A (ja) 2024-04-23
HRP20250632T1 (hr) 2025-07-18
AR125818A1 (es) 2023-08-16
TWI915553B (zh) 2026-02-21
EP4609865A2 (en) 2025-09-03
KR20240007152A (ko) 2024-01-16
JP7869248B2 (ja) 2026-06-02
MA64323B1 (fr) 2025-06-30
TW202311245A (zh) 2023-03-16
ES3031704T3 (en) 2025-07-10
CA3214626A1 (en) 2022-11-17
RS66893B1 (sr) 2025-07-31
US20240208928A1 (en) 2024-06-27
MX2023012907A (es) 2023-11-08
CR20230529A (es) 2023-12-04
LT4337652T (lt) 2025-06-25
IL307188A (en) 2023-11-01
AU2022275300A1 (en) 2023-09-21
CL2023003312A1 (es) 2024-06-21
HUE071498T2 (hu) 2025-09-28

Similar Documents

Publication Publication Date Title
SI4337652T1 (sl) Zaviralci NLRP3
IL287042A (en) Inflammatory inhibitors of nlrp3
IL280336A (en) NLRP3 inflammasome inhibitors
LT4363406T (lt) Nlrp3 inflamasomų inhibitoriai
EP4262807A4 (en) Azachinazoline pan-KRAS inhibitors
IL318258A (en) NLRP3 inflammasome inhibitors
IL315027A (en) Inhibitors of nlrp3
IL314049A (en) PARP7 inhibitors
GB202008201D0 (en) Inhibitor compounds
IL318533A (en) NLRP3 inflammasome inhibitors
IL325676A (en) Kat6 inhibitors
GB202004960D0 (en) Inhibitor compounds
GB202110373D0 (en) Inhibitor compounds
GB201905328D0 (en) Inhibitor compounds
IL315980A (en) EGFR inhibitors
SMT202500406T1 (it) Inibitori del tead
PT4337652T (pt) Inibidores do nlrp3
EP4263533C0 (en) Erap inhibitors
GB202117224D0 (en) Inhibitor compounds
GB202012969D0 (en) Inhibitor compounds
IL320219A (en) Inhibitors
IL313756A (en) Inhibitors of the sestrin-MAPK complex
HK40061653A (zh) Nlrp3炎性小体抑制剂
HK40122649A (en) Nlrp3 inhibitors
GB202112240D0 (en) Inhibitor compounds